LNP3693 STING Agonist Trial Analyzed at ESMO Congress

Lupin, a pharmaceutical company, will share new information about a promising medicine called LNP3693 at the ESMO Congress in Berlin, Germany, from October 17 to 21, 2025. This medicine is being tested to see if it can help fight cancer. The research shows how well LNP3693 works and if it’s safe for people with advanced cancers.

Key Points

• LNP3693 is a new medicine tested in cancer patients.
• The trial shows preliminary data on safety and how it works.
• Data presented at ESMO focuses on solid tumors & lymphoma.
• Researchers studied its effects on cancer cells in the body.
• The trial results highlight potential anti-tumor activity.
• Lupin’s research success reflects strong oncology drug development skills.

About the Trial

The presentation, titled “A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors & Lymphoma,” will be available on October 19, 2025, from 9:00 AM to 5:00 PM CEST. Scientists are looking at how well LNP3693 works in people with different types of cancer, including solid tumors and lymphoma. They’ll also be watching for any side effects.

Important Context

LNP3693 is a new drug called a “STING agonist.” This means it’s designed to stimulate the body’s own immune system to fight cancer. Lupin has been working on this research after successfully sharing information about another drug, LNP7457, at the ASCO conference in June 2025.

Vinita Gupta, CEO of Lupin, said that the ESMO’s recognition of their research in India shows how skilled their team is at developing and testing cancer drugs. This is a significant step forward in the development of new treatments.

“Effective cancer treatments require a collaborative approach, and we’re proud to share these results with the global oncology community.”